Positive guidance from the US FDA on Cu-64 SARTATE Phase III
Filed with ASX · · 3 pages · English
Clarity Pharmaceuticals Ltd. on 6ix
Story so far
- DISCO topline results: 64Cu-SARTATE is highly effective in detecting tumours in NET patients compared to SOC imaging. Phase III planning underway.
- Clarity receives US FDA Fast Track Designation for the treatment of metastatic castration-resistant prostate cancer patients with Cu-67 SAR-bisPSMA
- Clarity receives US FDA FTD for the treatment of mCRPC
Earlier from Clarity Pharmaceuticals
- AGM MD Presentation
- Clarity signs copper-67 Supply Agreement with Nusano
- Co-PSMA trial achieves primary endpoint
- S&P DJI Announces September 2025 Quarterly Rebalance
- Preliminary Final Report
Later from Clarity Pharmaceuticals
- Co-PSMA abstract accepted for oral presentation at EAU
- Co-PSMA abstract accepted for oral presentation at EAU Annual Congress 2026
- SECuRE trial to continue with no modifications to protocol
- SECuRE trial to continue with no modifications to protocol following Safety Review Committee meeting
- Quarterly Activities/Appendix 4C Cash Flow Report
Follow Clarity Pharmaceuticals into a list and get an email when it puts out news.
Follow Clarity Pharmaceuticals